TAM
HRTX icon

Tiverton Asset Management’s Heron Therapeutics HRTX Stock Holding History

Tiverton Asset Management’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$101K Hold
5,439
– – ﹤0.01% 644
2019
Q2 		$101K Buy
+5,439
New +$109K ﹤0.01% 623

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Tiverton Asset Management's HRTX Position: Q3 2019 in Review

Tiverton Asset Management held its Heron Therapeutics (HRTX) position steady in Q3 2019 at 5,439 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #644.

Tiverton Asset Management first reported a position in HRTX in Q2 2019 and has held it in 2 quarters since. 180 funds tracked by Wall St. Rank hold HRTX as of Q3 2019.

  • Tiverton Asset Management held 5,439 shares of Heron Therapeutics worth $101K as of Q3 2019.
  • Tiverton Asset Management left its Heron Therapeutics share count unchanged in Q3 2019.
  • Heron Therapeutics made up ﹤0.01% of Tiverton Asset Management's portfolio in Q3 2019, its #644 holding.
  • Tiverton Asset Management first reported a position in Heron Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 180 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2019.

Based on Tiverton Asset Management's 13F filing for Q3 2019, filed 13 Nov 2019.